COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
FRA:C43 - Deutsche Boerse Ag - NL0011832936 - Common Stock - Currency: EUR
Taking everything into account, C43 scores 8 out of 10 in our fundamental rating. C43 was compared to 50 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making C43 a very profitable company, without any liquidiy or solvency issues. C43 has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! Finally C43 also has an excellent dividend rating. These ratings would make C43 suitable for value and dividend and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year C43 was profitable.
In the past year C43 had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: C43 reported negative net income in multiple years.
Each year in the past 5 years C43 had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 20.60%, C43 belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
The Return On Equity of C43 (26.74%) is better than 76.92% of its industry peers.
Looking at the Return On Invested Capital, with a value of 21.60%, C43 belongs to the top of the industry, outperforming 88.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 49.94%, C43 belongs to the best of the industry, outperforming 98.08% of the companies in the same industry.
In the last couple of years the Profit Margin of C43 has grown nicely.
With an excellent Operating Margin value of 55.81%, C43 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
C43's Operating Margin has improved in the last couple of years.
C43's Gross Margin of 83.00% is amongst the best of the industry. C43 outperforms 86.54% of its industry peers.
In the last couple of years the Gross Margin of C43 has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), C43 is creating value.
The number of shares outstanding for C43 has been reduced compared to 1 year ago.
C43 has more shares outstanding than it did 5 years ago.
C43 has a better debt/assets ratio than last year.
2.2 Solvency
C43 has an Altman-Z score of 5.80. This indicates that C43 is financially healthy and has little risk of bankruptcy at the moment.
C43 has a Altman-Z score of 5.80. This is amongst the best in the industry. C43 outperforms 90.38% of its industry peers.
C43 has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
C43's Debt to FCF ratio of 0.01 is amongst the best of the industry. C43 outperforms 98.08% of its industry peers.
C43 has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.00, C43 belongs to the best of the industry, outperforming 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
C43 has a Current Ratio of 4.19. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
C43's Current ratio of 4.19 is amongst the best of the industry. C43 outperforms 96.15% of its industry peers.
C43 has a Quick Ratio of 3.91. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of C43 (3.91) is better than 96.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1315.29% over the past year.
The Earnings Per Share has been growing by 85.20% on average over the past years. This is a very strong growth
C43 shows a strong growth in Revenue. In the last year, the Revenue has grown by 187.55%.
C43 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.68% yearly.
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
Based on estimates for the next years, C43 will show a very strong growth in Earnings Per Share. The EPS will grow by 29.02% on average per year.
The Revenue is expected to grow by 22.67% on average over the next years. This is a very strong growth
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.98, the valuation of C43 can be described as very cheap.
C43's Price/Earnings ratio is rather cheap when compared to the industry. C43 is cheaper than 92.31% of the companies in the same industry.
C43's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.50.
Based on the Price/Forward Earnings ratio of 8.09, the valuation of C43 can be described as reasonable.
Based on the Price/Forward Earnings ratio, C43 is valued cheaper than 84.62% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.44. C43 is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
96.15% of the companies in the same industry are more expensive than C43, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of C43 indicates a rather cheap valuation: C43 is cheaper than 94.23% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
C43 has an outstanding profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as C43's earnings are expected to decrease with -27.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
C43 has a Yearly Dividend Yield of 3.85%.
The stock price of C43 dropped by -28.24% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 3.00, C43 pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.35, C43 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
5.2 History
The dividend of C43 is nicely growing with an annual growth rate of 7.41%!
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
C43 pays out 24.09% of its income as dividend. This is a sustainable payout ratio.
C43's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
FRA:C43 (4/29/2025, 7:00:00 PM)
48.8
-1.2 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 | ||
| P/S | 3.21 | ||
| P/FCF | 5.46 | ||
| P/OCF | 5.27 | ||
| P/B | 1.72 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 3.83 |
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROCE | 24.88% | ||
| ROIC | 21.6% | ||
| ROICexc | 28.38% | ||
| ROICexgc | 129.8% | ||
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% | ||
| FCFM | 58.76% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y181.33%
ROICexcg growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 46.02% | ||
| Cap/Sales | 2.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.77% | ||
| Profit Quality | 117.65% | ||
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.8 |
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A